Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
BRAF mutation
Case report
Dabrafenib-trametinib combination
EGFR mechanism of resistance
Leptomeningeal disease
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
13
02
2021
revised:
13
05
2021
accepted:
16
05
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Molecular sequencing after highly potent targeted gene inhibitors have suggested resistant tumors can display substantial heterogeneity. Among these various mechanisms of resistance, secondary mutations on targetable oncogenes have been identified.
Identifiants
pubmed: 34590033
doi: 10.1016/j.jtocrr.2021.100192
pii: S2666-3643(21)00051-5
pmc: PMC8474423
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100192Informations de copyright
© 2021 The Authors.
Références
Cell Rep Med. 2020 Apr 21;1(1):
pubmed: 32483558
Oncologist. 2017 Jul;22(7):823-833
pubmed: 28526719
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Clin Lung Cancer. 2012 Nov;13(6):458-63
pubmed: 22402083